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Abstract
Background: In a previous study, we found that heat shock
protein 27 (HSP27) was over-expressed in gastric adenocar-
cinoma (GA) tissue. In this study, our goal was to further
verify the expression profile of HSP27 in patients with GA.
Methods: Western blot and immunohistochemistry were
employed to determine HSP27 expression in 50 paired tumor
and adjacent normal tissue. ELISA was used to quantify
serum HSP27 concentrations in the same 50 GA patients and
50 healthy individuals.
Results: Compared to adjacent normal tissues, HSP27 was
over-expressed in 25 (50%, ps0.000) and 24 (48%, ps
0.000) cases of GA tissue by Western blot and immuno-
histochemistry, respectively. ELISA revealed significantly
higher serum concentrations of HSP27 in patients with GA
patients (means986 pg/mL) compared to healthy individu-
als (means573 pg/mL) (ps0.003). In addition, infection
with Helicobacter pylori (HP) in healthy individuals was
associated with increased expression of HSP27 in both gas-
tric mucosa and serum.
Conclusions: These data suggest that HSP27 is over-
expressed in GA tissue and serum concentrations of HSP27
are increased in patients with GA. Over-expression of HSP27
may indicate a gastric malignant/infectious process. The
detection of serum HSP27 concentrations by ELISA may be
useful for screening for GA.
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Introduction
Heat shock protein 27 (HSP27) is a member of the small
molecular weight HSP family and is a major molecular chap-
erone with a role in regulating normal cell physiology and
the cellular stress response (1–3). HSP27 prevents protein
aggregation, helps in the correct folding of proteins, and
assists with the formation of multi-protein complexes, and
recovers the protein structure for proteins that denature dur-
ing cell stress (4, 5). Besides these main chaperone functions,
HSP27 has been associated with apoptosis and cell prolif-
eration and differentiation (6, 7). Additionally, HSP27 is
over-expressed in many kinds of cancers, although its role in
cancer remains unclear (8–10).
Gastric cancer is a common and serious malignancy. More
than 870,000 new cases are diagnosed worldwide each year,
and it has the second highest death rate among all cancers.
Previously, we analyzed protein expression patterns in paired
gastric adenocarcinoma (GA) and non-neoplastic mucosa
tissues using two-dimensional polyacrylamide gel electro-
phoresis (2D-PAGE) and matrix-assisted laser desorption
ionization-time of flight mass spectrometry (MALDI-TOF/
TOF MS) (11). This analysis identified 42 proteins differ-
entially expressed two-fold or greater between tumor and
adjacent normal tissues. HSP27 was one of the proteins
shown to be over-expressed in GA tissue (11). The present
study was performed to further verify its expression profile
in patients with GA. To accomplish this objective, expression
of HSP27 in GA and matched adjacent normal tissue were
detected by Western blot and immunohistochemistry. Also,
we measured the concentration of HSP27 in sera of patients
with GA and healthy individuals using ELISA.
Materials and methods
Tissue samples and serum samples
Fifty GA and matched normal gastric mucosa tissue samples were
obtained. Diagnosis of GA was confirmed by analysis of tissue
(Table 1), and matched normal gastric mucosa tissue samples were
a minimum of 10 cm from the edge of the cancer tissue. The sam-
ples were obtained from fresh surgical material of GA patients from
Dongfang Hospital (Fuzhou, Fujian, P.R. China) within 30 min of
resection. The samples were stored immediately at –808C until anal-
ysis. In addition, regular paraffin embedded blocks were prepared.
For ELISA, we collected serum samples from the 50 patients with
GA prior to surgery. We also collected 50 serum samples from
healthy individuals at Dongfang Hospital. The age range of the
patients with GA was 30–87 years (median 59 years), and the age
range for healthy individuals was 28–76 years (median 57 years).
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Table 1 HSP27 expression in tumor tissues and sera from patients with gastric adenocarcinomas.
Patient Sex Age, HSP27 expression Pathological HSP27 Histological Differentiation TNM




1 F 64 q1.6 q2.4 Mild AtroG 1866 Intestinal High T2N0MX
2 M 75 1.0 1.0 Severe ActiG 881 Intestinal Poor T3N2MX
3 M 55 ND ND Unchanged 56 Intestinal Moderate T4N2MX
4 M 58 q4.6 q3.9 Unchanged 1072 Intestinal Poor T2N0MX
5 M 58 q2.1 q5.7 Unchanged 1025 Diffuse Signet-ring T3N1MX
6 M 61 1.0 1.0 Severe ActiG 1307 Intestinal Poor T2N1MX
7 M 32 q2.5 q3.6 Unchanged 1133 Intestinal Moderate T2N0MX
8 M 48 q9.0 q8.3 Unchanged 991 Intestinal Moderate T1N0MX
9 F 47 –0.8 –0.6 Severe IM 370 Intestinal High T2N0MX
10 F 53 1.0 1.0 Moderate AtroG 328 Diffuse Signet-ring T2N1MX
with mild ActiG
11 M 49 q3.6 q7.2 Unchanged 2500 Diffuse Mucinous T4N2Mx
12 F 71 ND 1.0 Severe AtroG 75 Intestinal Poor T2N1MX
13 M 51 –0.6 –0.7 Severe ActiG 400 Intestinal Moderate T1N0MX
14 F 72 q4.1 q1.7 Mild AtroG 1131 Intestinal Moderate T2N0Mx
15 F 58 1.0 1.0 Severe ActiG 725 Intestinal Moderate T2N1Mx
16 M 59 q7.2 q11.6 Unchanged 2500 Intestinal Poor T4N1Mx
17 M 87 q5.4 q4.1 Unchanged 1902 Intestinal Moderate T3N1Mx
18 F 48 q3.2 1.0 Severe ActiG 980 Intestinal Poor T3N1Mx
19 M 54 1.0 1.0 Moderate ActiG 426 Intestinal Moderate T3N2Mx
20 M 74 q1.4 q1.7 Mild AtroG 1083 Intestinal Moderate T1N0Mx
21 M 48 –0.7 –0.8 Moderate IM 218 Intestinal Poor T2N0Mx
22 M 47 q8.3 q8.0 Unchanged 2500 Diffuse Signet-ring T3N0Mx
23 M 43 1.0 1.0 Moderate IM 568 Intestinal Poor T3N2Mx
24 M 46 ND 1.0 Severe AtroG 67 Diffuse Mucinous T3N0Mx
25 M 69 1.0 1.0 Moderate IM 801 Intestinal Moderate T2N2Mx
26 M 65 q10.4 q6.5 Unchanged 2500 Intestinal Poor T3N1Mx
27 F 50 q1.9 q1.6 Mild AtroG 1018 Intestinal Early stage GA T1N0Mx
28 M 72 q2.5 q3.4 Mild AtroG 1212 Intestinal Moderate T2N0Mx
29 M 41 ND ND Unchanged 51 Intestinal High T2N1Mx
30 F 30 1.0 1.0 Severe IM 512 Intestinal Poor T3N1Mx
31 M 69 q6.6 q4.3 Unchanged 1574 Intestinal Poor T3N0Mx
32 F 38 1.0 1.0 Severe Actig 846 Diffuse Signet-ring T3N1Mx
33 M 51 q4.9 q2.9 Mild AtroG 2481 Intestinal High T4N2Mx
34 F 36 1.0 1.0 Moderate ActiG 631 Intestinal Poor T3N0Mx
35 F 67 1.0 –0.8 Severe IM 466 Intestinal Early stage GA T1N0Mx
36 M 75 –0.6 1.0 Moderate ActiG 307 Diffuse Mucinous T3N1Mx
37 F 74 q5.2 q9.9 Unchanged 2301 Intestinal Poor T3N2Mx
38 F 61 q3.3 q7.4 Unchanged 2094 Intestinal Moderate T3N1Mx
39 M 48 ND ND Unchanged 177 Intestinal Moderate T1N0Mx
40 M 50 q4.4 q2.1 Mild AtroG 1234 Intestinal Poor T3N1Mx
41 M 43 1.0 1.0 Moderate ActiG 258 Intestinal Moderate T2N0MX
42 F 76 q2.1 q1.8 Mild AtroG 1005 Diffuse Signet-ring T2N2MX
43 M 68 1.0 1.0 Mild IM 203 Intestinal Moderate T2N1MX
44 M 81 1.0 1.0 Mile IM 341 Intestinal Moderate T3N1MX
45 M 74 q2.9 q3.0 Unchanged 1157 Intestinal Poor T2N1MX
46 M 53 q3.1 q3.3 Unchanged 1348 Diffuse Mucinous T3N2MX
47 F 75 1.0 1.0 Mild IM 162 Intestinal Moderate T1N0MX
48 F 69 q3.6 q2.4 Mild AtroG 1292 Intestinal Poor T3N1MX
49 F 79 q1.4 q1.6 Mild AtroG 997 Intestinal Moderate T2N1MX
50 M 77 1.0 1.0 Moderate Atrog 298 Intestinal Poor T2N0MX
with mild Actig
ND, none detected; M, male; F, female; IHC, immunohistochemistry; GA, gastric adenocarcinomas. aValues indicate the ratios of relative
intensity (nomalized to b-tubulin) measured in GA vs. paired non-neoplastic tissue; ‘‘q’’ indicates over-expression; ‘‘–’’ indicates down-
expression, and 1.0 is considered no changes. bValues indicate the ratios of GA vs. paired non-neoplastic tissue; ‘‘q’’ indicates over-
expression; ‘‘–’’ indicates down-expression, and 1.0 is considered no changes. ActiG indicates chronic active gastritis; AtroG indicates
atrophy gastritis; IM indicates intestinal metaplasia.
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Ethics
Use of the serum samples, and GA tissue and paired non-neoplastic
mucosa tissue for this study was approved by the Dongfang Hospital
Ethical Committees.
Western blots for HSP27
Tissues lysates were prepared according to the method described
previously (11). The protein concentrations in the GA and matched
normal tissue samples were measured using a BCA Protein Quant
Kit (Bio-Rad, Hercules, CA, USA). Equal amounts of protein
(35 mg) were subjected to sodium dodecyl sulfate polyacrylamide
gel electrophoresis (SDS-PAGE) (12%). The blots were transferred
onto PVDF membranes (Amersham Bioscience, Piscataway, NJ,
USA) and incubated with goat anti-human HSP27 (Santa Cruz Bio-
technology, San Diego, CA, USA) at a dilution of 1:1000. The
primary antibodies were detected with horseradish peroxidase-
conjugated mouse anti-goat antibodies (Santa Cruz Biotechnology)
at a dilution of 1:1000. The immunoreactive protein bands were
visualized using enhanced chemiluminscent reagents (Amersham
Bioscience). Western blotting of the same sample with anti-b-tubu-
lin (Santa Cruz Biotechnology) was used as the control. The signal
intensity was measured with ImageQuant TL v2003.03 analysis
software (Amersham Bioscience). The relative intensity (RI) of
HSP27 was normalized to b-tubulin, and the ratios of RI of GA vs.
paired non-neoplastic tissue were calculated.
Immunohistochemistry for human HSP27
The blocks of paraffin-embedded human GA and matched normal
tissue sections were sectioned, placed on glass slides, and baked for
2 h at 608C. Tissues were deparaffinized with three changes of
xylene, then with a series of ethanol (100%, 95%, 95% and 80%),
followed by rinsing with distilled water for 5 min. Antigen retrieval
was performed by putting the slides into boiling citrate buffer
(1008C) for 90 s, and 3% H2O2 was used to quench endogenous
peroxidase interference. After washing with phosphate buffered
saline (PBS), the slides were covered with preimmune rabbit serum
for 10 min and washed again in PBS. Primary goat anti-human
HSP27 antibody (Santa Cruz Biotechnology), at a dilution of 1:200,
was added to each sample, followed by incubation for 3 h at room
temperature (RT). After three washes in PBS, the slides were incu-
bated with a biotin-labeled rabbit anti-goat IgG secondary antibody
(Santa Cruz Biotechnology) for 10 min at RT. The slides were
washed in PBS again, and incubated with streptavidin-HRP (Santa
Cruz Biotechnology) for an additional 10 min at RT. Finally, the
slides were incubated with 0.5% 3,39-diaminobenzidine tetrahydro-
chloride (DAB) in PBS containing 0.03% hydrogen peroxide for
10 min and counterstained with hematoxylin for 30 s. The slides
were viewed with a microscope and the staining results were quan-
tified using Motic Med 6.0A Material Image Analysis System
(Motic, Beijing, China). The grade was expressed using a gray scale
value, and the ratios of GA vs. paired non-neoplastic tissue were
calculated. Samples incubated with PBS rather instead of the pri-
mary antibody were used as the negative control, and paraffin-
embedded liver sections with known positive immunoreactivity for
HSP27 were used as the positive control.
ELISA for human HSP27
Sera from the same 50 GA patients used for immunohistochemistry
and 50 healthy individuals were collected, and the concentration of
HSP27 was quantitated by ELISA (R&D Systems, Minneapolis,
MN, USA) according to the manufacturer’s instructions. The ELISA
plates were measured using the Labsystems microtiter plate reader
(Thermo, Waltham, MA, USA) at 450 nm. p-Values were obtained
using the Wilcoxon two-sample-test.
ELISA for detection of human anti-Helicobacter pylori
(HP) IgG in control group
Human anti-HP IgG was detected in sera from the 50 healthy indi-
viduals using ELISA (Biocup, Shenzen, Guangdong, China) accord-
ing to the manufacturer’s instructions (12). Briefly, 100 mL of serum
diluted 1:100 in PBS was added to ELISA plates that were pre-
coated with purified HP antigens. After incubation and washing,
peroxidase-conjugated anti-human IgG diluted 1:5000 was added
and the plates were incubated and washed again. The color was
developed by adding tetramethylbenzidine (TMB) and the reaction
was stopped by the addition of H2SO4. In the final step, the ELISA
plates were measured with the Labsystems microtiter plate reader
(Thermo) at 450 nm. Samples with absorbance values greater than
the cut-off threshold (0.21) were considered positive.
Results
The over-expression of HSP27 in GA tissues
identified by Western blot
To verify the expression profile of HSP27 in GA tissue, 50
cases of GA and paired non-neoplastic tissues were exam-
ined by Western blot with anti-HSP27. In 25 of the 50 GA
cases, HSP27 had increased expression compared to the oth-
er tissue (50%, Table 1, ps0.000, Wilcoxon signed-ranks
test). Over-expression of HSP27 was not correlated with age
()50 vs. F50, ps0.667, x2-test), gender (female vs. male,
ps0.061, x2-test), histological type (intestinal vs. diffuse,
ps0.654, x2-test), TNM stage (ps0.763, x2-test), and dif-
ferentiation grade (high vs. poor, ps0.512, x2-test).
For the remaining 25 cases, no significant difference in
the expression of HSP27 was identified in 16 cases (32%).
No signal was observed from either tissue in five cases
(10%), and four samples from patients with cancer had
weaker expression compared with their paired non-cancerous
tissue (8%, Table 1, Figure 1).
Representative results from eight patients are shown in
Figure 1. A reactive band of molecular weight 27 kDa was
found in GA tissue from seven of eight cases. HSP27 was
over-expressed in samples 1, 4, 5, 7 and 8 of the GA tissue,
and the intensities of HSP27 expression between GA and
paired non-neoplastic tissues were nearly identical in samples
2 and 6, while no signal was detected in either the GA or
non-neoplastic tissue from sample 3.
Over-expression of HSP27 in GA tissues identified
by immunohistochemistry
To identify the localized expression patterns of HSP27 in
cancer tissue, samples were examined by immunohistoche-
mistry with anti-HSP27. To elucidate whether the patholog-
ical changes in mucosa affected HSP27 expression, we
examined the 50 paired non-neoplastic mucosa for the chron-
ic active gastritis (ActiG) (monocyte infiltration or neutrophil
infiltration), gastric atrophy, and intestinal metaplasia (IM).
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Figure 1 Western blot analysis of HSP27 expression.
Over-expression of HSP27 in GA tissue (Ca) compared to paired non-neoplastic tissue (N) confirmed by Western blotting. Equal amounts
of protein from each sample were probed with anti-b-tubulin as control. The signal intensity measured by ImageQuant TL v2003.03 analysis
software, the relative intensity (RI) of HSP27 normalized to b-tubulin, and the ratios of RI of GA vs. paired non-neoplastic tissue are at
the bottom. HSP27 was over-expressed in samples 1, 4, 5, 7 and 8 from tissues with cancer. The intensity of HSP27 expression in cancer
and non-cancerous tissues was nearly identical in samples 2 and 6. No signal was detected (ND) in either the cancerous or non-cancerous
tissue samples from sample 3.
Figure 2 Immunohistochemical analysis of HSP27 expression in
gastric adenocarcinoma.
HSP27 was expressed more strongly in the cytoplasm of GA tissue
than in the non-neoplastic tissue. The expression of HSP27 in nor-
mal stomach (A–B) and GA (C–D). Images on the left panel were
made at =100 magnification; the images on the right were mag-
nified images (=400) of the boxed sections depicted at left.
The degree of inflammation was graded as normal, mild,
moderate, or severe according to the updated Sydney system
using visual analog scales applied to microscopic examina-
tion results (13). Immunohistochemistry staining revealed
that HSP27 was localized to the cytoplasm of cancer tissue
(Figure 2C and D) in 24 of the GA samples (24/50, 48%).
In contrast, only weak signals were found in the paired non-
neoplastic mucosa (Figure 2A and B). Based on the immu-
nohistochemistry, HSP27 expression was higher in patients
with GA compared to the paired normal controls (ps0.000,
Wilcoxon signed-ranks test). Similar to the results from the
Western blots, over-expression of HSP27 was not correlated
with increased age ()50 vs. F50 years, ps0.432, x2-test),
gender (female vs. male, ps0.056, x2-test), histological type
(intestinal vs. diffuse, ps0.820, x2-test), TNM stage
(ps0.759, x2-test), or differentiation grade (high vs. poor,
ps0.951, x2-test).
In the immunohistochemistry analysis, no significant dif-
ference between cancer and paired non-neoplastic mucosa
cells was seen in 19 pairs (38%). The paired non-neoplastic
mucosa in these cases included one, two, and three cases
with severe, moderate, and mild IM, respectively, two cases
with severe gastric atrophy, two cases with moderate gastric
atrophy with mild active gastritis, and five and four cases
with severe and moderate active gastritis, respectively. In
three (6%) other cases, we detected no HSP27 signal from
either tissue. Finally, in the remaining four pairs (8%), the
GA samples (cases 9, 13, 21 and 35) had weaker HSP27
signals than their paired non-cancerous tissues. The non-can-
cerous tissues of three of these four cases had IM (two severe
and one moderate). The fourth of these cases had severe
active gastritis. In the 24 GA samples with over expression
of HSP27, the paired non-neoplastic mucosa had either mild
gastric atrophy (10 cases), or were without any significant
change (14 cases, Table 1).
The results of histological analysis were consistent with
Western blot results showing that HSP27 was over-expressed
in the majority of cancer tissues. These results indicate that
certain pathological changes in the non-neoplastic mucosa,
such as ActiG, gastric atrophy, and IM can show increased
HSP27 expression which may mask increased expression by
the tumor.
HSP27 concentrations in human serum samples
To investigate whether there is a link between intracellular
and extracellular HSP27 concentrations in gastric neoplasia
and to investigate whether HSP27 secreted in patients with
GA could be of diagnostic significance, we used ELISA to
measure HSP27 concentrations in serum samples from 50
patients with GA and 50 healthy individuals. All 50 GA
patients had detectable HSP27 in their serum (Figure 3). The
mean serum HSP27 concentrations were 986.40"742.51
pg/mL and 572.54"506.16 pg/mL for GA patients and
healthy persons, respectively. In most cases, HSP27 concen-
tration was significantly higher in the GA patients (ps0.003,
Wilcoxon two-sample test). Our results suggest that a pos-
sible screening threshold for GA is 573 pg/mL. In addition,
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Figure 3 Serum HSP27 concentration by ELISA assay.
HSP27 serum concentrations were significantly higher in patients
with GA compared to healthy individuals (ps0.003). The mean
concentration of HSP27 was 986 pg/mL (range 51–2500 pg/mL)
for GA patients and 573 pg/mL (range, 43–2500 pg/mL) for healthy
individuals. Box plots show serum concentrations of HSP27. The
lines inside the boxes are the mean. The box represents the interval
between the 25th and 75th percentiles except for data )1500
pg/mL for healthy individuals and )2000 pg/mL for GA patients,
which are shown as circles. Seven out of 50 serum samples from
patients with GA were )2000 pg/mL, and 4 out of 50 serum sam-
ples from healthy individuals were )1500 pg/mL.
all GA patients with tissues over-expressing HSP27 had
increased serum HSP27 concentrations (shown in Table 1).
The HSP27 serum concentrations were correlated positively
with HSP27 expression in GA tissues as detected by Western
blot and immunohistochemistry.
ELISA for detection of human anti-HP IgG
in control group
Anti-HP IgG seropositivity was detected in 46 of 50 healthy
individuals. The results indicated that HP infection may be
related with increased HSP27 expression in the serum of
controls.
Discussion
When a cell becomes cancerous, its stress level can increase
resulting in changes in pH, cell metabolism, and other cel-
lular events. These changes can disrupt the cell cycle and
DNA synthesis, leading to gene mutations and neoplastic
progression (14–16). Some cancerous cells over-express
HSP27 which may increase cell proliferation and metastasis.
Over expression of HSP27 has been reported for a wide vari-
ety of tumors, and is associated with poor prognosis of some
tumors, including liver and prostate carcinoma (17–24).
The over-expression of HSP27 in gastric cancer has been
observed by several studies (8, 25, 26). In gastric cancer,
over-expression of HSP27 may be associated with metastasis
to the lymph nodes, advanced stage (III and IV) cancer, and
shorter overall survival of patients (27, 28), indicating that
HSP27 has prognostic significance for gastric cancer. Addi-
tionally, HSP27 expression was closely related to gastric
tumor size, and the presence of organ metastases (29). How-
ever, another study found that HSP27 was not present in
metastatic gastric tumors, and was only detectable in samples
from non-metastatic gastric cancer tissue (26). None of these
studies measured HSP27 serum concentrations to investigate
if there is a link between intracellular and extracellular
HSP27 concentrations in gastric neoplasia. Previously, we
found HSP27 over-expression in 5 of 10 GA tissues using a
proteomics technique. Here, we extended that study to more
GA patients and investigated the link between intracellular
and extracellular HSP27 concentration.
Both Western blotting and immunohistochemistry revealed
over-expression of HSP27 in most tumor tissues. Addition-
ally, the concentration of HSP27 in serum samples from
patients with GA was significantly higher than that from
healthy individuals. Also, serum HSP27 concentrations were
positively correlated with HSP27 expression in GA tissue
detected by Western blot and immunohistochemistry. Almost
all of the patients with HSP27 over-expression in GA tissues
also had increased serum HSP27 concentrations.
Although HSP27 expression in cancer tissue and paired
non-neoplastic mucosa was nearly identical in case 6 (Figure
1), this non-neoplastic mucosa had strong positive expression
of HSP27. Infection with HP is also associated with mucosal
damage and increased stress production, leading to increased
expression of HSP27 (30, 31). Using the rapid urease test
(RUT) (32), we determined that nine of the non-neoplastic
mucosa tissues had HP infection, among these nine samples
with HP infection were case 6 and five other cases (cases 9,
13, 21, 35, and 36), in which the paired non-neoplastic
mucosa had higher HSP27 expression than the GA tissue.
Although HP infection may have resulted in an apparent lack
of over-expression in tissue from case 6 GA tissue, the serum
concentration of HSP27 (1307 pg/mL) was higher than the
mean for patients with GA.
In addition to HP infection, paired non-neoplastic mucosa
with ActiG, gastric atrophy, and IM also had increased
HSP27 expression, leading to a decreased ratio of HSP27
expression in cancer tissue to normal tissue (Table 1). These
pathological changes in non-neoplastic mucosa may mask
the increased expression by the tumor and explain why only
50% of GA tissues had an increase in HSP27 expression. In
contrast, these pathological changes were not associated with
HSP27 serum concentrations. In almost all cases, HSP27
serum concentrations were closely associated with the over-
expression of HSP27 in GA tissue. Future studies should
focus on the link between HSP27 serum concentration and
over-expression in GA tissue.
HP infection increases HSP27 expression (30, 31).
Because 46 of the 50 healthy individuals were infected with
HP, the control group might also have had increased HSP
expression in their sera due to HP infection. These increased
HSP27 concentrations in the control individuals may lead to
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overlapping distributions of HSP27 in serum in GA patients
and healthy controls.
HSP27 is constitutively expressed at low levels in the
cytosol of most human cells, including cells located in gastric
mucosa. These low levels of expression likely indicate an
important role for HSP27 in cellular homeostasis and gastric
mucosa defense (33–36). In accordance with previous
results, we also found HSP27 expressed in majority of gastric
mucosa. Although it is accepted that HSP27 is expressed in
normal epithelium (37), HSP27-positive healthy individuals
may have experienced microbial or viral infection, resulting
in stressed mucosa (38). We identified some cases with no
HSP27 expression in either the non-neoplastic gastric muco-
sa or GA tissue. The lack of HSP27 expression was due to
limited sensitivity of current methods, individual differences,
or other reasons (37, 38). These results should be confirmed
in future studies.
The data from this study also indicated that over-expres-
sion of HSP27 was not related to patient’s age, gender, TNM
stage, histological type and differentiation grade. Due to the
over-expression of HSP27 being found in GA from early
through late stages, we thus speculate that HSP27 might be
associated with early stage carcinogenesis.
In conclusion, our results demonstrate that HSP27 is over-
expressed in GA tissues, and increased in sera from patients
with GA. Over-expression of HSP27 may indicate a malig-
nant or infectious process, and the measurement of serum
HSP27 concentrations by ELISA may be useful for screening
for GA.
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